Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Heart; Dysfunction Postoperative, Cardiac Surgery

In brief

The objective of this study is to show that ranolazine is a safe, viable and potent alternative for post-operative atrial fibrillation suppression in patients undergoing cardiac surgery

Key facts

Study ID

NCT01352416

Run by

Corewell Health East

People needed

15

Starts

2010-09-01

Expected to finish

2012-11-01

Last updated by the study team

2017-01-06

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Indications for cardiac surgery (CABG, valve surgery or CABG and valve surgery, Able to provide informed consent.

You may not qualify if…

• Documented atrial fibrillation within the previous 3 months
• Ongoing therapy with suppressive antiarrhythmic drugs
• Patient currently on digoxin
• Emergent surgery
• Patient receiving hemodialysis
• Concomitant use of ketoconazole, diltiazem, verapamil
• Known tolerance or hypersensitivity to ranolazine
• Pregnant individuals
• MAZE procedure (is a surgical ablation to treat atrial fibrillation) performed during concurrent cardiac surgery

Where it is running

• William Beaumont Hospital — Royal Oak, Michigan, United States
• William Beaumont Hospital — Troy, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.